Glorincor and Biocon presented opportunities for Eurasian market in treatment cancer at Eurasian Cancer Screening Conference.
Glorincor company in cooperation with its partner Biocon Limited took part in the Eurasian Cancer Screening Conference, which held 17 – 18th, May in Belarus (Minsk).
Leading oncologists from 37 countries visited the conference sessions. The conference focused on evaluation of effectiveness of cancer screening and treatment programs in Eastern Europe, central Asia and Baltic countries. Major topics were concentrated on challenging problems in breast, cervical, colorectal and prostate cancer programs.
The organizers of the conference are the Alexandrov National Cancer Center of Belarus, the United States National Cancer Institute, the Piedmont Reference Center for Epidemiology and Cancer Prevention, the Belarusian society of oncologists.
At the conference Glorincor widely presented Biocon’s cutting-edge product to treat the breast cancer – TRASTUZUMAB, which was registered by FDA 1st of December 2017 and many other countries. Currently, this Biocon’s TRASTUZUMAB is under registration in most of CIS countries, including Belarus.